The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
August 14, 2017
Quarterly Article
Sara Rosenbaum
Oct 4, 2024
September 2024
Sep 18, 2024
Back to The Milbank Quarterly
The spectacular failure of the “repeal and replace” Obamacare saga that collapsed in July offers an opportunity to reflect. A political and policy debacle of epic proportions, the entire experience represents the GOP’s breathtaking failure to grasp how deeply health reform has permeated the US social fabric and the extent to which the public has come to expect that government will assure them access to affordable health insurance. To paraphrase Chief Justice John Roberts in King v Burwell,1 people want government to improve coverage, not destroy it.2
Another lesson of the summer is the folly of ignoring facts. Advocates of repeal and replace deluded themselves into believing that they could simply trash-talk out of existence the Congressional Budget Office (CBO) estimates—presented through nonpartisan analysis accompanied by dense tables—documenting the harm that the House and Senate proposals would cause millions of people,3,4 especially older low- and moderate-income Americans who make up a crucial part of Republicans’ own political base. In its typical low-key but thorough fashion, CBO made it clear that the legislative strategy for bringing down the cost of coverage meant cutting off access to affordable insurance among the people most in need of health care while degrading the value of private insurance for the rest of the population.
For those who have not followed US health policy over decades, the size and strength of the outcry over Medicaid may have come as a shock. Anyone who paid close attention to House Speaker Paul Ryan’s writings, speeches, and public statements over the years knew that, in his view, unraveling Medicaid was the centerpiece of the repeal and replace effort. This meant more than eliminating the health reform’s Medicaid expansion for poor adults, now in place in 32 states. In order to generate the necessary savings to give tax breaks to wealthy individuals and corporations while also breaking the back of the nation’s largest means-tested legal entitlement, the proposals would have undone the underlying Medicaid program itself, destroying the federal funding base on which the program has rested for over half a century. According to CBO, by 2036, federal Medicaid spending would have declined by one third.
The battle over Medicaid’s future revealed the extent of GOP policy ignorance regarding Medicaid’s reach in the health care system. Along with its smaller companion Children’s Health Insurance Program (whose future funding will become a front-burner issue when Congress reconvenes in September), Medicaid today reaches nearly 75 million people.5 But beneficiary numbers alone don’t convey Medicaid’s importance.6 Its reach reflects a national policy response to many social, economic, and public health factors: child and family poverty; an aging society coupled with the absence of a long-term care policy; public health threats, both naturally occurring and man-made; and a rise in the number of people living with major disabilities and chronic illnesses. Medicaid pays for nearly 1 in 2 US births, 2 in 5 children, half of all nursing home care, and the lion’s share of home and community-based services and supports. Particularly in medically underserved communities, Medicaid keeps clinics and pharmacies open. Medicaid is the principal source of funding for the neonatal intensive care units, children’s hospitals, and visiting nurse programs on which we all depend.
Another lesson found in the collapse of repeal and replace is just how much direct government involvement actually is necessary to make private health insurance markets work. Medicaid is a hardy perennial; as a legal entitlement to coverage, Medicaid acts like insurance, but it relies on broad public health principles. Resting on general funding, Medicaid is built to embrace risk rather than avoid it. Its beneficiaries are the poorest and sickest among us; the services it covers are the highest cost. Medicaid is what we turn to when hurricane survivors need access to care, when an opioid crisis consumes communities across the nation, when a deadly pandemic strikes low-income communities whose living conditions place them at heightened risk for the rapid spread of infection.
By contrast, private insurance, especially the individual insurance market, is more akin to a hothouse flower. In order to survive, this market needs a great deal of government gardening. As a nation, we have decided—as reflected in the Affordable Care Act—that we want individuals to have access to private health insurance when their employers don’t offer workplace health benefits, when workplace health benefits are unaffordable to workers or their families, when people lose their jobs because of underlying economic shifts or for health reasons, or when a life change such as a divorce creates a sudden need for an individual coverage policy.
To accomplish this goal, conditions need to be exactly right. A predominantly young and healthy pool of people must support the market’s backbone. This group needs to be economically incentivized to buy coverage and keep themselves continually covered. Premiums need to be affordable. Policies must provide good coverage and enough of the cost of covered services to keep care affordable and make people feel that buying the policy was worth it to begin with. Insurers need to be backstopped against unanticipated cost surges arising from a less healthy risk pool or a higher-than-expected rate of high-cost illnesses and disabilities among policyholders and their families. Insurers must have sufficient flexibility over benefit, network, and cost-sharing design to avoid cost risks, especially those posed by long-term health problems.
Assuring these conditions demands nuanced and close attention and a more considered, bipartisan approach toward creating the circumstances that will allow the market to stabilize: creating enrollment incentives; providing income-based premium assistance; active outreach to get people to enroll; subsidies that keep health care affordable; and backstopping insurers against unanticipated costs. And as the insurance industry itself would be the first to say, preserving the individual insurance market also means preserving Medicaid to do all of the heavy lifting that we simply cannot expect a form of coverage as delicate as the individual insurance market to do. Private insurance may be able to substitute for Medicaid to a very modest degree; we may see states increasingly interested in testing the use of Medicaid to buy private insurance policies—but only for their very healthiest enrollees.
But if we want the hothouse flower to flourish, we need the hardiest of perennials to remain strong.
References
Sara Rosenbaum J.D. is Emerita Professor of Health Law and Policy at George Washington University’s Milken Institute School of Public Health. Previously she served as the Harold and Jane Hirsh Professor of Health Law and Policy and as founding Chair of the Department of Health Policy.
Professor Rosenbaum has devoted her career to health justice for medically underserved populations. She is a member of the National Academies of Sciences, Engineering, and Medicine, served on CDC’s Director’s Advisory Committee and the CDC Advisory Committee on Immunization Practice (ACIP), and was a founding Commissioner of Congress’s Medicaid and CHIP Payment and Access Commission (MACPAC), which she chaired from January 2016 through April 2017.
Professor Rosenbaum is the recipient of many honors and awards including the National Academy of Medicine’s Adam Yarmolinsky Medal, awarded for distinguished service to a member from a discipline outside the health and medical sciences, the American Public Health Association Executive Director Award for Service, and the Association of Schools and Programs of Public Health Welch-Rose Award for Lifetime Contributions to the Health of the Public.